O2Line™ System
Type 1 Diabetes
Pre-clinicalActive
Key Facts
About Persista Bio
Persista Bio is pioneering a novel drug delivery platform designed to overcome the major hurdles in cell therapy: immune rejection, cell viability, and patient burden. Its lead program targets Type 1 diabetes with an implant that encapsulates insulin-secreting stem cells and provides them with oxygen, aiming to automatically regulate blood glucose for years. Founded in 2021 and based on licensed technology from Cornell University and Giner, Inc., the company is in the preclinical stage, having demonstrated proof-of-concept in diabetic rat models. Persista Bio's platform is also designed to be translatable to other metabolic and enzyme deficiency disorders.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |